Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial - Annals of Oncology
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - Clinical Breast Cancer
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Puma Biotechnology Surging
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now | npj Breast Cancer
Puma Biotechnology Files NDS For NERLYNX In Canada
Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Nerlynx (neratinib) Cancer Medication - Cancer Health
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma shares jump 40% after FDA review but brief leaves scope for AdComm grilling and neratinib rejection | Fierce Biotech
Puma Biotech presents mixed data on neratinib in glioblastoma
Puma Biotechnology
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Puma Biotechnology
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
